Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC-FOLFOX plus Atezolizumab and Bevacizumab in High-risk HCC
NCT05886465Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- May 2023
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab, oxaliplatin, fluorouracil, folinic acid in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
atezolizumabbevacizumaboxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05886465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886465.